BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Page J. Nonalcoholic fatty liver disease: the hepatic metabolic syndrome. J Am Acad Nurse Pract. 2012;24:345-351. [PMID: 22672485 DOI: 10.1111/j.1745-7599.2012.00716.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Hearn C, Ellington BJ, Jones R. The Role of the Nurse Practitioner in the Management of Nonalcoholic Fatty Liver Disease. Gastroenterol Nurs 2018;41:424-6. [PMID: 30272604 DOI: 10.1097/SGA.0000000000000394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang XQ, Ju J, Hu MM, Gao F, Yan FY. Progress in treatment of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2014; 22(10): 1378-1383 [DOI: 10.11569/wcjd.v22.i10.1378] [Reference Citation Analysis]
3 Tanaka K, Masaki Y, Tanaka M, Miyazaki M, Enjoji M, Nakamuta M, Kato M, Nomura M, Inoguchi T, Kotoh K, Takayanagi R. Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World J Gastroenterol 2014; 20(10): 2653-2663 [PMID: 24627601 DOI: 10.3748/wjg.v20.i10.2653] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
4 la Buscató E, Blöcher R, Lamers C, Klingler FM, Hahn S, Steinhilber D, Schubert-Zsilavecz M, Proschak E. Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors. J Med Chem 2012;55:10771-5. [PMID: 23130964 DOI: 10.1021/jm301194c] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
5 Montemayor S, Mascaró CM, Ugarriza L, Casares M, Llompart I, Abete I, Zulet MÁ, Martínez JA, Tur JA, Bouzas C. Adherence to Mediterranean Diet and NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study. Nutrients 2022;14:3186. [DOI: 10.3390/nu14153186] [Reference Citation Analysis]
6 Ao N, Yang J, Wang X, Du J. Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. Hepatol Res. 2016;46:343-353. [PMID: 26147696 DOI: 10.1111/hepr.12551] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
7 Li YY. Recent progress in research of nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2013; 21(2): 109-115 [DOI: 10.11569/wcjd.v21.i2.109] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
8 Kim H, Bartley GE, Young SA, Seo KH, Yokoyama W. Altered hepatic gene expression profiles associated with improved fatty liver, insulin resistance, and intestinal permeability after hydroxypropyl methylcellulose (HPMC) supplementation in diet-induced obese mice. J Agric Food Chem 2013;61:6404-11. [PMID: 23742138 DOI: 10.1021/jf400545w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]